Melanoma is not rare in absolute terms. An estimated 104,960 new cases will be diagnosed in the U.S. in 2025, making it about 5.1% of all new cancers. But among skin cancers specifically, melanoma is the uncommon one: it accounts for roughly 22% of skin cancer cases worldwide, while basal cell and squamous cell carcinomas make up the other 78%. That distinction matters because melanoma is far more dangerous per case than those more common types.
Melanoma by the Numbers
The incidence rate in the U.S. is 21.9 new cases per 100,000 people per year. To put that in perspective, if you gathered 100,000 Americans in a stadium, about 22 of them would be diagnosed with melanoma this year. The death rate is much lower: 2.0 per 100,000 per year, reflecting the fact that most melanomas are caught early enough to treat successfully.
Globally, about 325,000 melanoma cases were reported in 2020, compared to nearly 1.2 million cases of non-melanoma skin cancer. So while melanoma gets outsized attention relative to its share of skin cancer diagnoses, that attention is warranted. It causes a disproportionate number of skin cancer deaths.
How Rates Vary by Country
Where you live dramatically affects your risk. Australia and New Zealand have the highest melanoma rates in the world, with an age-adjusted incidence of about 54 per 100,000 people, more than double the U.S. rate. Strong UV exposure, a predominantly fair-skinned population, and an outdoor culture all contribute. Several Northern European countries follow: Switzerland at 32.1, Norway at 30.4, Sweden at 30.7, Denmark at 28.5, and the Netherlands at 28.7 per 100,000. The U.S. sits at 21.9, and the United Kingdom at 23.0.
In countries closer to the equator with darker-skinned populations, melanoma rates are far lower. Geography and skin pigmentation together create a wide global range in how “rare” melanoma actually is.
Age and Sex Make a Big Difference
Melanoma risk is not evenly distributed between men and women, and it shifts with age in a surprising pattern. Women under 50 actually have about twice the incidence of men in the same age group. After 50, that ratio flips. By age 60, men have twice the incidence of women. By 70, men have three times the rate. Overall, men are diagnosed at a rate of 27.4 per 100,000 compared to 16.8 for women, and men are about one and a half times more likely to die from it.
The reasons aren’t fully understood but likely involve a combination of biological differences in skin and immune function, differences in sun exposure patterns, and differences in how quickly people seek medical attention for changing moles.
Melanoma Compared to Other Skin Cancers
If you’ve heard melanoma called “the deadly skin cancer,” that framing is accurate but incomplete. In 2020, non-melanoma skin cancers caused over 63,700 deaths worldwide, and recent research suggests their collective mortality may rival or exceed melanoma’s. The difference is that melanoma is far more lethal on a case-by-case basis. A single melanoma diagnosis carries more risk than a single basal cell carcinoma, which rarely spreads beyond the skin.
Roughly 1 in every 5 skin cancers is a melanoma. The other 4 are overwhelmingly basal cell or squamous cell carcinomas, which grow slowly and are usually cured with minor procedures. Melanoma’s tendency to spread to lymph nodes, lungs, liver, and brain is what sets it apart.
Survival Rates by Stage
How dangerous a melanoma diagnosis is depends almost entirely on when it’s found. For localized melanoma, meaning it hasn’t spread beyond the original skin site, the five-year survival rate is above 99%. That’s essentially the same as someone without cancer. The vast majority of melanomas are caught at this stage.
Once melanoma reaches nearby lymph nodes (regional stage), five-year survival drops to 76%. If it has spread to distant organs (metastatic), the rate falls to 35%. Across all stages combined, the overall five-year survival rate is 95%, which reflects how many cases are caught early. That 95% figure can be misleading if you focus only on advanced disease, but it does show that early detection transforms this cancer from life-threatening to highly treatable.
Rare Subtypes Within Melanoma
Not all melanomas are the typical sun-related type that develops on frequently exposed skin. Acral lentiginous melanoma (ALM) grows on the palms, soles of the feet, or under fingernails and toenails. It’s genuinely rare, representing just 0.8% of melanomas in non-Hispanic white individuals. But among Hispanic, Black, American Indian/Alaska Native, and Asian/Pacific Islander populations, ALM accounts for up to 19.1% of melanoma cases. This subtype is often diagnosed later because it appears in areas people don’t routinely check, and it isn’t driven by UV exposure the way most melanomas are.
Mucosal melanoma, which develops in the lining of the mouth, nasal passages, or other internal surfaces, is even less common. These rare subtypes are important to know about because they challenge the assumption that melanoma only happens to fair-skinned people who spend a lot of time in the sun.
Your Individual Risk in Context
For the average American, the lifetime risk of developing melanoma is roughly 1 in 38, though this varies significantly by race and ethnicity. Fair-skinned individuals with a history of sunburns, a large number of moles, or a family history of melanoma face substantially higher odds. People with darker skin have a much lower overall incidence, but when melanoma does occur, it tends to be diagnosed at a later stage, partly because of lower suspicion and partly because the subtypes that affect darker skin (like ALM) appear in less obvious locations.
So is melanoma rare? Compared to the common skin cancers, yes. Compared to cancers overall, it’s moderately common, ranking fifth among new cancer diagnoses in the U.S. And in countries like Australia, it’s one of the most frequently diagnosed cancers, period. The answer depends entirely on the frame of reference, but with over 100,000 new U.S. cases expected this year, it’s not a disease anyone should consider unlikely.